Indiana University and PharmatrophiX Present Findings on Alzheimer's Disease Therapeutic

Researchers from Indiana University and PharmatrophiX presented key findings at the Alzheimer's Association International Conference (AAIC) in London, focusing on the performance of the oral therapeutic LM11A-31 in slowing the decline of brain functional network connectivity in mild to moderate Alzheimer's disease.

The analysis, utilizing a novel brain metabolic functional-network connectivity mapping technique, suggests LM11A-31 may support the integrity of brain communication networks. The study demonstrated a statistically significant slowing of network function decline compared to placebo, with these changes linked to cognitive domains and synaptic resilience.

"LM11A-31 is designed to protect the synapses – connections between neurons – that enable the brain to function as an integrated network," stated Dr. Frank M. Longo, Co-Founder of PharmatrophiX. "These findings, along with prior preclinical studies and Phase 2a trial biomarker results, strengthen our understanding of how our mechanism of action may influence the underlying biology of Alzheimer's disease."

The new brain mapping technology, developed at Indiana University School of Medicine, uses brain metabolic measurements to create network maps that quantify network function and reveal the progression of neurodegenerative diseases. Researchers observed dose-dependent effects of LM11A-31 on brain metabolic connectivity and functional systems linked to cognition. The data suggests the drug may help preserve and reorganize brain networks supporting cognitive function.

These findings provide encouraging evidence that LM11A-31 could help preserve cognitive function-supporting brain networks. PharmatrophiX is advancing the clinical development of the program for individuals living with Alzheimer's disease.